Identification of retinoic acid in a high content screen for agents that overcome the anti-myogenic effect of TGF-beta-1

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Krueger, Chateen ^a   Hoffmann, F Michael ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; 4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ALITRETINOIN; CAPTOPRIL; EPIGALLOCATECHIN GALLATE; ESTROGEN; LOSARTAN; METRIBOLONE; MYOSIN HEAVY CHAIN; PROTEIN INHIBITOR; RELAXIN; RESVERATROL; RETINOIC ACID; SIS 3; SMAD3 PROTEIN; TRANILAST; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VITAMIN D; 1,3 DIOXOLANE DERIVATIVE; 4 (5 BENZO(1,3)DIOXOL 5 YL 4 PYRIDIN 2 YL 1H IMIDAZOL 2 YL)BENZAMIDE; 4-(5-BENZO(1,3)DIOXOL-5-YL-4-PYRIDIN-2-YL-1H-IMIDAZOL-2-YL)BENZAMIDE; ANTIOXIDANT; BENZAMIDE DERIVATIVE; CATECHIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG DERIVATIVE; STILBENE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VITAMIN;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL DIFFERENTIATION; CELL STRAIN; CELL STRAIN C2C12; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG SCREENING; MOUSE; MUSCLE DEVELOPMENT; MYOBLAST; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; TRANSCRIPTION INITIATION; ANIMAL; CELL LINE; CELL PROLIFERATION; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; SIGNAL TRANSDUCTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIOXIDANTS; BENZAMIDES; CAPTOPRIL; CATECHIN; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; DIOXOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MUSCLE DEVELOPMENT; MYOBLASTS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; STILBENES; TRANSFORMING GROWTH FACTOR BETA1; TRETINOIN; VITAMIN D; VITAMINS;

EID: 78649776286     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015511     Document Type: Article

References (97)

1. Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685-700.
2. ten Dijke P, Hill CS (2004) New insights into TGF-beta-Smad signalling. Trends Biochem Sci 29: 265-273.
3. Sporn MB, Roberts AB (1990) TGF-beta: problems and prospects. Cell Regul 1: 875-882.
4. Siegel PM, Massague J (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3: 807-821.
5. Rosenbloom J, Castro SV, Jimenez SA (2010) Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med 152: 159-166.
6. Massague J, Cheifetz S, Endo T, Nadal-Ginard B (1986) Type beta transforming growth factor is an inhibitor of myogenic differentiation. Proc Natl Acad SciUS A 83: 8206-8210.
7. Olson EN, Sternberg E, Hu JS, Spizz G, Wilcox C (1986) Regulation of myogenic differentiation by type beta transforming growth factor. J Cell Biol 103: 1799-1805.
8. Brennan TJ, Edmondson DG, Li L, Olson EN (1991) Transforming growth factor beta represses the actions of myogenin through a mechanism independent of DNA binding. Proc Natl Acad Sci U S A 88: 3822-3826.
9. Liu D, Black BL, Derynck R (2001) TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. Genes Dev 15: 2950-2966.
10. Liu D, Kang JS, Derynck R (2004) TGF-beta-activated Smad3 represses MEF2- dependent transcription in myogenic differentiation. EMBO J 23: 1557-1566.
11. Kollias HD, Perry RL, Miyake T, Aziz A, McDermott JC (2006) Smad7 promotes and enhances skeletal muscle differentiation. Mol Cell Biol 26: 6248-6260.
12. McPherron AC, Lawler AM, Lee SJ (1997) Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387: 83-90.
13. Amthor H, Huang R, McKinnell I, Christ B, Kambadur R, et al. (2002) The regulation and action of myostatin as a negative regulator of muscle development during avian embryogenesis. Dev Biol 251: 241-257.
14. Bernasconi P, Di Blasi C, Mora M, Morandi L, Galbiati S, et al. (1999) Transforming growth factor-beta1 and fibrosis in congenital muscular dystrophies. Neuromuscul Disord 9: 28-33.
15. Gosselin LE, Williams JE, Deering M, Brazeau D, Koury S, et al. (2004) Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle. Muscle Nerve 30: 645-653.
16. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G (1993) Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 122: 103-111.
17. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA (2002) Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 3: 349-363.
18. Li Y, Foster W, Deasy BM, Chan Y, Prisk V, et al. (2004) Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. Am J Pathol 164: 1007-1019.
19. Li Y, Huard J (2002) Differentiation of muscle-derived cells into myofibroblasts in injured skeletal muscle. Am J Pathol 161: 895-907.
20. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, et al. (2007) Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13: 204-210.
21. Dezawa M, Ishikawa H, Itokazu Y, Yoshihara T, Hoshino M, et al. (2005) Bone marrow stromal cells generate muscle cells and repair muscle degeneration. Science 309: 314-317.
22. Peault B, Rudnicki M, Torrente Y, Cossu G, Tremblay JP, et al. (2007) Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Ther 15: 867-877.
23. Reimann J, Irintchev A, Wernig A (2000) Regenerative capacity and the number of satellite cells in soleus muscles of normal and mdx mice. Neuromuscul Disord 10: 276-282.
24. Lavoie P, Robitaille G, Agharazii M, Ledbetter S, Lebel M, et al. (2005) Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J Hypertens 23: 1895-1903.
25. Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, et al. (2001) Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 103: 789-791.
26. Sugaru E, Nakagawa T, Ono-Kishino M, Nagamine J, Tokunaga T, et al. (2006) Enhanced effect of combined treatment with SMP-534 (antifibrotic agent) and losartan in diabetic nephropathy. Am J Nephrol 26: 50-58.
27. Sugaru E, Nakagawa T, Ono-Kishino M, Nagamine J, Tokunaga T, et al. (2007) Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (antifibrotic agent) and losartan in db/db mice. Nephron Exp Nephrol 105: e45-e52.
28. Yu L, Border WA, Anderson I, McCourt M, Huang Y, et al. (2004) Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int 66: 1774-1784.
29. Yingling JM, Blanchard KL, Sawyer JS (2004) Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 3: 1011-1022.
30. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, et al. (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62: 65-74.
31. Watt KI, Jaspers RT, Atherton P, Smith K, Rennie MJ, et al. (2010) SB431542 treatment promotes the hypertrophy of skeletal muscle fibers but decreases specific force. Muscle & Nerve.
32. Garber K (2009) Companies waver in efforts to target transforming growth factor beta in cancer. J Natl Cancer Inst 101: 1664-1667.
33. Dietz HC (2010) TGF-beta in the pathogenesis and prevention of disease: a matter of aneurysmic proportions. J Clin Invest 120: 403-407.
34. Portier GL, Benders AG, Oosterhof A, Veerkamp JH, van Kuppevelt TH (1999) Differentiation markers of mouse C2C12 and rat L6 myogenic cell lines and the effect of the differentiation medium. In Vitro Cell Dev Biol Anim 35: 219-227.
35. Mori S, Tokuyama K (2007) Variation in ACE activity affects myogenic differentiation in C2C12 cells. Biochem Biophys Res Commun 353: 369-375.
36. De Albuquerque DA, Saxena V, Adams DE, Boivin GP, Brunner HI, et al. (2004) An ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine lupus nephritis. Kidney Int 65: 846-859.
37. Wengrower D, Zanninelli G, Pappo O, Latella G, Sestieri M, et al. (2004) Prevention of fibrosis in experimental colitis by captopril: the role of tgf-beta1. Inflamm Bowel Dis 10: 536-545.
38. Mori S, Tokuyama K (2007) ACE activity affects myogenic differentiation via mTOR signaling. Biochem Biophys Res Commun 363: 597-602.
39. Izumi K, Mizokami A, Li YQ, Narimoto K, Sugimoto K, et al. (2009) Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes. Prostate 69: 1222-1234.
40. Chakrabarti R, Subramaniam V, Abdalla S, Jothy S, Prud'homme GJ (2009) Tranilast inhibits the growth and metastasis of mammary carcinoma. Anticancer Drugs 20: 334-345.
41. Iwata Y, Katanosaka Y, Shijun Z, Kobayashi Y, Hanada H, et al. (2005) Protective effects of Ca2+ handling drugs against abnormal Ca2+ homeostasis and cell damage in myopathic skeletal muscle cells. Biochem Pharmacol 70: 740-751.
42. Jinnin M, Ihn H, Tamaki K (2006) Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol 69: 597-607.
43. Li ZB, Kollias HD, Wagner KR (2008) Myostatin directly regulates skeletal muscle fibrosis. J Biol Chem 283: 19371-19378.
44. Yun BG, Matts RL (2005) Hsp90 functions to balance the phosphorylation state of Akt during C2C12 myoblast differentiation. Cell Signal 17: 1477-1485.
45. Yun CH, Yoon SY, Nguyen TT, Cho HY, Kim TH, et al. (2010) Geldanamycin inhibits TGF-beta signaling through induction of Hsp70. Arch Biochem Biophys 495: 8-13.
46. Wrighton KH, Lin X, Feng XH (2008) Critical regulation of TGFbeta signaling by Hsp90. Proc Natl Acad Sci U S A 105: 9244-9249.
47. Heeg MH, Koziolek MJ, Vasko R, Schaefer L, Sharma K, et al. (2005) The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int 68: 96-109.
48. Negishi S, Li Y, Usas A, Fu FH, Huard J (2005) The effect of relaxin treatment on skeletal muscle injuries. Am J Sports Med 33: 1816-1824.
49. Samuel CS (2005) Relaxin: antifibrotic properties and effects in models of disease. Clin Med Res 3: 241-249.
50. Messina S, Bitto A, Aguennouz M, Mazzeo A, Migliorato A, et al. (2009) Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: a comparison study with methylprednisolone. Exp Neurol 220: 349-358.
51. Brisdelli F, D'Andrea G, Bozzi A (2009) Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr Drug Metab 10: 530-546.
52. Hemdan DI, Hirasaka K, Nakao R, Kohno S, Kagawa S, et al. (2009) Polyphenols prevent clinorotation-induced expression of atrogenes in mouse C2C12 skeletal myotubes. J Med Invest 56: 26-32.
53. Park CE, Kim MJ, Lee JH, Min BI, Bae H, et al. (2007) Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp Mol Med 39: 222-229.
54. Dirks Naylor AJ (2009) Cellular effects of resveratrol in skeletal muscle. Life Sci 84: 637-640.
55. Wyke SM, Russell ST, Tisdale MJ (2004) Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation. Br J Cancer 91: 1742-1750.
56. Nakae Y, Hirasaka K, Goto J, Nikawa T, Shono M, et al. (2008) Subcutaneous injection, from birth, of epigallocatechin-3-gallate, a component of green tea, limits the onset of muscular dystrophy in mdx mice: a quantitative histological, immunohistochemical and electrophysiological study. Histochem Cell Biol 129: 489-501.
57. Brown D, Hikim AP, Kovacheva EL, Sinha-Hikim I (2009) Mouse model of testosterone-induced muscle fiber hypertrophy: involvement of p38 mitogenactivated protein kinase-mediated Notch signaling. J Endocrinol 201: 129-139.
58. Kovacheva EL, Hikim AP, Shen R, Sinha I, Sinha-Hikim I. Testosterone supplementation reverses sarcopenia in aging through regulation of myostatin, c-Jun NH2-terminal kinase, Notch, and Akt signaling pathways. Endocrinology 151: 628-638.
59. Vlahopoulos S, Zimmer WE, Jenster G, Belaguli NS, Balk SP, et al. (2005) Recruitment of the androgen receptor via serum response factor facilitates expression of a myogenic gene. J Biol Chem 280: 7786-7792.
60. Lee HJ, Yun CH, Lim SH, Kim BC, Baik KG, et al. (2007) SRF is a nuclear repressor of Smad3-mediated TGF-beta signaling. Oncogene 26: 173-185.
61. Chipuk JE, Cornelius SC, Pultz NJ, Jorgensen JS, Bonham MJ, et al. (2002) The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3. J Biol Chem 277: 1240-1248.
62. Matsuda T, Yamamoto T, Muraguchi A, Saatcioglu F (2001) Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. J Biol Chem 276: 42908-42914.
63. Enns DL, Tiidus PM (2010) The influence of estrogen on skeletal muscle: sex matters. Sports Med 40: 41-58.
64. Pedraza-Alva G, Zingg JM, Donda A, Perez-Martinez L (2009) Estrogen receptor regulates MyoD gene expression by preventing AP-1-mediated repression. Biochem Biophys Res Commun 389: 360-365.
65. Kahlert S, Grohe C, Karas RH, Lobbert K, Neyses L, et al. (1997) Effects of estrogen on skeletal myoblast growth. Biochem Biophys Res Commun 232: 373-378.
66. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H (2007) RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 6: 793-810.
67. Duester G (2008) Retinoic acid synthesis and signaling during early organogenesis. Cell 134: 921-931.
68. Niederreither K, Dolle P (2008) Retinoic acid in development: towards an integrated view. Nat Rev Genet 9: 541-553.
69. Arnold HH, Gerharz CD, Gabbert HE, Salminen A (1992) Retinoic acid induces myogenin synthesis and myogenic differentiation in the rat rhabdomyosarcoma cell line BA-Han-1C. J Cell Biol 118: 877-887.
70. Carnac G, Albagli-Curiel O, Levin A, Bonnieu A (1993) 9-cis-retinoic acid regulates the expression of the muscle determination gene Myf5. Endocrinology 133: 2171-2176.
71. Xiao Y, Grieshammer U, Rosenthal N (1995) Regulation of a muscle-specific transgene by retinoic acid. J Cell Biol 129: 1345-1354.
72. Zhu GH, Huang J, Bi Y, Su Y, Tang Y, et al. (2009) Activation of RXR and RAR signaling promotes myogenic differentiation of myoblastic C2C12 cells. Differentiation 78: 195-204.
73. Stio M, Celli A, Treves C (2001) Synergistic anti-proliferative effects of vitamin D derivatives and 9-cis retinoic acid in SH-SY5Y human neuroblastoma cells. J Steroid Biochem Mol Biol 77: 213-222.
74. Stio M, Celli A, Treves C (2002) Synergistic effect of vitamin D derivatives and retinoids on C2C12 skeletal muscle cells. IUBMB Life 53: 175-181.
75. Blutt SE, Allegretto EA, Pike JW, Weigel NL (1997) 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 138: 1491-1497.
76. Bastie JN, Balitrand N, Guidez F, Guillemot I, Larghero J, et al. (2004) 1 alpha,25-dihydroxyvitamin D3 transrepresses retinoic acid transcriptional activity via vitamin D receptor in myeloid cells. Mol Endocrinol 18: 2685-2699.
77. Roberts AB, Sporn MB (1992) Mechanistic interrelationships between two superfamilies: the steroid/retinoid receptors and transforming growth factorbeta. Cancer Surv 14: 205-220.
78. Mucida D, Cheroutre H (2007) TGFbeta and retinoic acid intersect in immuneregulation. Cell Adh Migr 1: 142-144.
79. Yu Z, Xing Y (2006) All-trans retinoic acid inhibited chondrogenesis of mouse embryonic palate mesenchymal cells by down-regulation of TGF-beta/Smad signaling. Biochem Biophys Res Commun 340: 929-934.
80. Zhang H, Li N, Tang Y, Wu W, Zhang Q, et al. (2009) Negative functional interaction of retinoic acid and TGF-beta signaling mediated by TG-interactingfactor during chondrogenesis. Cell Physiol Biochem 23: 157-164.
81. Pendaries V, Verrecchia F, Michel S, Mauviel A (2003) Retinoic acid receptors interfere with the TGF-beta/Smad signaling pathway in a ligand-specific manner. Oncogene 22: 8212-8220.
82. Redlich CA, Delisser HM, Elias JA (1995) Retinoic acid inhibition of transforming growth factor-beta-induced collagen production by human lung fibroblasts. Am J Respir Cell Mol Biol 12: 287-295.
83. Glick AB, Flanders KC, Danielpour D, Yuspa SH, Sporn MB (1989) Retinoic acid induces transforming growth factor-beta 2 in cultured keratinocytes and mouse epidermis. Cell Regul 1: 87-97.
84. Borger DR, Mi Y, Geslani G, Zyzak LL, Batova A, et al. (2000) Retinoic acid resistance at late stages of human papillomavirus type 16-mediated transformation of human keratinocytes arises despite intact retinoid signaling and is due to a loss of sensitivity to transforming growth factor-beta. Virology 270: 397-407.
85. Nunes I, Kojima S, Rifkin DB (1996) Effects of endogenously activated transforming growth factor-beta on growth and differentiation of retinoic acidtreated HL-60 cells. Cancer Res 56: 495-499.
86. Danielpour D (1996) Induction of transforming growth factor-beta autocrine activity by all-trans-retinoic acid and 1 alpha,25-dihydroxyvitamin D3 in NRP-152 rat prostatic epithelial cells. J Cell Physiol 166: 231-239.
87. Imai S, Okuno M, Moriwaki H, Muto Y, Murakami K, et al. (1997) 9,13-di-cis- Retinoic acid induces the production of tPA and activation of latent TGF-beta via RAR alpha in a human liver stellate cell line, LI90. FEBS Lett 411: 102-106.
88. Kojima S, Rifkin DB (1993) Mechanism of retinoid-induced activation of latent transforming growth factor-beta in bovine endothelial cells. J Cell Physiol 155: 323-332.
89. La P, Morgan TA, Sykes SM, Mao H, Schnepp RW, et al. (2003) Fusion proteins of retinoid receptors antagonize TGF-beta-induced growth inhibition of lung epithelial cells. Oncogene 22: 198-210.
90. Cao Z, Flanders KC, Bertolette D, Lyakh LA, Wurthner JU, et al. (2003) Levels of phospho-Smad2/3 are sensors of the interplay between effects of TGF-beta and retinoic acid on monocytic and granulocytic differentiation of HL-60 cells. Blood 101: 498-507.
91. Lengfelder E, Saussele S, Weisser A, Buchner T, Hehlmann R (2005) Treatment concepts of acute promyelocytic leukemia. Crit Rev Oncol Hematol 56: 261-274.
92. Thielitz A, Krautheim A, Gollnick H (2006) Update in retinoid therapy of acne. Dermatol Ther 19: 272-279.
93. Chroni E, Monastirli A, Tsambaos D (2010) Neuromuscular adverse effects associated with systemic retinoid dermatotherapy: monitoring and treatment algorithm for clinicians. Drug Saf 33: 25-34.
94. Lens M, Medenica L (2008) Systemic retinoids in chemoprevention of onmelanoma skin cancer. Expert Opin Pharmacother 9: 1363-1374.
95. Miller VA, Benedetti FM, Rigas JR, Verret AL, Pfister DG, et al. (1997) Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 15: 790-795.
96. Kempf W, Kettelhack N, Duvic M, Burg G (2003) Topical and systemic retinoid therapy for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 17: 1405-1419.
97. Zhang C, Duvic M (2003) Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. Dermatol Ther 16: 322-330.